Cardiovascular Outcomes with Canagliflozin vs. Non-SGLT2 Inhibitor Antidiabetes Drugs

Trials have shown that sodium-glucose cotransporter-2 (SGLT2) inhibitors, which block glucose reabsorption in the proximal renal tubule, lower risks for adverse cardiovascular (CV) outcomes in patients with type 2 diabetes with established, or high risk for, CV disease (NEJM JW Gen Med Oct 15 2015 and N Engl J Med 2015; 373:2117; NEJM JW Gen Med Aug 1 2017 and N Engl J Med 2017; 377:644). But how SGLT2 inhibitors compare with other antidiabetes drugs regarding these outcomes is unknown. In this population-based, retrospective cohort study, drawn from a U.S. commercial healthcare database, researchers compared CV outcomes in patients with type 2 diabetes who used the SGLT2 inhibitor canagliflozin (Invokana) or other antidiabetes drugs.

Resear…